Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 3/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | DHFR | P00374 | 1/20 | 0.42 |
| ▸ | MPO | P05164 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL816712 | 0.81 | TRPA1 (0.50) | TRPA1ATMALDH1A1ESR1ESR2 | |
| SCHEMBL310386 | 0.79 | KMT2A (0.52) | TRPA1ATMALDH1A1ESR1ESR2 | |
| SCHEMBL6547365 | 0.79 | TRPA1 (0.48) | TRPA1ATMALDH1A1ESR1ESR2 | |
| SCHEMBL9864607 | 0.79 | ESR1 (0.52) | TRPA1ATMALDH1A1ESR1ESR2 | |
| SCHEMBL16950882 | 0.79 | TRPA1 (0.48) | TRPA1ATMALDH1A1ESR1ESR2 | |
| SCHEMBL16955880 | 0.79 | TRPA1 (0.48) | TRPA1ATMALDH1A1ESR1ESR2 | |
| SCHEMBL7124951 | 0.79 | TRPA1 (0.48) | TRPA1ATMALDH1A1ESR1ESR2 | |
| SCHEMBL29515031 | 0.79 | KMT2A (0.52) | TRPA1ATMALDH1A1ESR1ESR2 | |
| SCHEMBL11300973 | 0.77 | TRPA1 (0.46) | TRPA1ATMALDH1A1ESR1ESR2 | |
| SCHEMBL501719 | 0.77 | ESR1 (0.50) | TRPA1ATMALDH1A1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0741741-B1 | MODIFIED OLIGONUCLEOTIDES | NOVARTIS AG (CH) | 2002-08-28 | — | — | EP | claimed |
| US-6066447-A | INCLUDING NUCLEOSIDE DIMERS WITH MODIFIED BACKBONES; FOR VIRICIDES AND ANTISENSE AGENTS | NOVARTIS CORPORATION (US) | 2000-05-23 | — | — | US | claimed |
| WO-1998000434-A1 | MODIFIED OLIGONUCLEOTIDES | NOVARTIS AG (CH) | 1998-01-08 | — | — | WO | claimed |
| EP-0538194-B1 | Bicyclic nucleosides, oligonucleotides, their method of preparation and intermediates therein | CIBA GEIGY AG (CH) | 1997-06-04 | — | — | EP | claimed |
| US-5610300-A | ANTIVIRAL, ANTIPROLIFERATIVE, ANTISENSE TECHNOLOGY, DIAGNOSIS | CIBA-GEIGY CORPORATION (US) | 1997-03-11 | — | — | US | claimed |
| EP-0741741-A1 | MODIFIED OLIGONUCLEOTIDES | Novartis AG (CH) | 1996-11-13 | — | — | EP | claimed |
| WO-1996019478-A1 | 6'-SUBSTITUTED CARBOCYCLIC NUCLEOSIDES | NOVARTIS AG (CH) | 1996-06-27 | — | — | WO | claimed |
| WO-1996006102-A1 | PROCESS FOR THE PREPARATION OF OLIGOSACCHARIDE MIXTURES | CIBA-GEIGY AG (CH) | 1996-02-29 | — | — | WO | claimed |
| US-5461152-A | Nucleoside intermediates for antisense oligonucleotides, antiviral agents | CIBA-GEIGY CORPORATION (US) | 1995-10-24 | — | — | US | claimed |
| WO-1995020597-A1 | MODIFIED OLIGONUCLEOTIDES | CIBA-GEIGY AG (CH) | 1995-08-03 | — | — | WO | claimed |
| US-5393878-A | Pyrimidine nucleosides having cyclopentafuran skeleton | CIBA-GEIGY CORPORATION (US) | 1995-02-28 | — | — | US | claimed |
| US-5332814-A | Process for the preparation of carbacyclic nucleosides, and intermediates | CIBA-GEIGY CORPORATION (US) | 1994-07-26 | — | — | US | claimed |
| US-5319080-A | Antiviral agents | CIBA-GEIGY CORPORATION (US) | 1994-06-07 | — | — | US | claimed |
| EP-0577558-A2 | Carbocyclic nucleosides having bicyclic rings, oligonucleotides therefrom, process for their preparation, their use and intermediates | CIBA-GEIGY AG (CH) | 1994-01-05 | — | — | EP | claimed |
| EP-0542681-A1 | Process for the preparation of carbocyclic nucleosides and its intermediates | CIBA-GEIGY AG (CH) | 1993-05-19 | — | — | EP | claimed |
| EP-0538194-A1 | Bicyclic nucleosides, oligonucleotides, their method of preparation and intermediates therein | CIBA-GEIGY AG (CH) | 1993-04-21 | — | — | EP | claimed |
| US-20050159374-A1 | 2'-Substituted nucleosides and oligonucleotide derivatives | NOVARTIS AG (CH) | 2005-07-21 | — | — | US | disclosed |
| US-6670468-B1 | Aminoalkylation at the 2' position | NOVARTIS AG (CH) | 2003-12-30 | — | — | US | disclosed |
| EP-0542681-A1 | Process for the preparation of carbocyclic nucleosides and its intermediates | CIBA-GEIGY AG (CH) | 1993-05-19 | — | — | EP | disclosed |
| EP-0538194-A1 | Bicyclic nucleosides, oligonucleotides, their method of preparation and intermediates therein | CIBA-GEIGY AG (CH) | 1993-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159374-A1 | 2'-Substituted nucleosides and oligonucleotide derivatives | TYMP, NUDT1, POLB | TRPA1 3902/4885ATM 3726/4885ALDH1A1 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.